Pacira BioSciences
PCRX
187 hedge funds and large institutions have $3.03B invested in Pacira BioSciences in 2015 Q2 according to their latest regulatory filings, with 31 funds opening new positions, 73 increasing their positions, 63 reducing their positions, and 47 closing their positions.
33% more capital inflows, than outflows
Capital inflows: $739M | Capital outflows: $554M
30% more call options, than puts
Call options by funds: $31.6M | Put options by funds: $24.3M
16% more repeat investments, than reductions
Existing positions increased: 73 | Existing positions reduced: 63
6.32% more ownership
Funds ownership: 110.73% → 117.05% (+6.3%)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
9% less funds holding
Funds holding: 205 → 187 (-18)
34% less first-time investments, than exits
New positions opened: 31 | Existing positions closed: 47
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Investors US
Denver,
Colorado
|
+$124M |
| 2 |
HCM
Hoplite Capital Management
New York
|
+$99.4M |
| 3 |
Westfield Capital Management
Boston,
Massachusetts
|
+$60.3M |
| 4 |
Goldman Sachs
New York
|
+$58.9M |
| 5 |
Visium Asset Management
New York
|
+$48.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jennison Associates
New York
|
-$92.5M |
| 2 |
RS Investment Management
San Francisco,
California
|
-$54.3M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$35.5M |
| 4 |
Eagle Asset Management
St Petersburg,
Florida
|
-$29.5M |
| 5 |
Hodges Capital Management
Dallas,
Texas
|
-$26.2M |
PCRX Hedge Fund Activity: Q2 2015 in Review
187 of the 3,730 institutional investors tracked by Wall St. Rank reported a position in Pacira BioSciences (PCRX) for Q2 2015, worth a combined $3.03B — down 15% from $3.59B a quarter earlier.
Sellers outnumbered buyers: 47 funds closed out of PCRX and 31 opened new positions — a net loss of 16 holders — while 63 trimmed existing stakes and 73 added.
The largest buyer was Janus Henderson Investors US, adding an estimated $124M. The largest seller was Jennison Associates, cutting an estimated $92.5M.
- 187 institutional investors held Pacira BioSciences (PCRX) as of Q2 2015, down from 205 in Q1 2015.
- Funds reported $3.03B of Pacira BioSciences stock for Q2 2015, down 15% quarter-over-quarter.
- 31 funds opened new Pacira BioSciences positions in Q2 2015 and 47 closed out, a net change of -16 holders.
- The largest Pacira BioSciences buyer in Q2 2015 was Janus Henderson Investors US, an estimated $124M added.
- The largest Pacira BioSciences seller in Q2 2015 was Jennison Associates, an estimated $92.5M sold.
Based on aggregated 13F filings for Q2 2015.